Ofatumumab treatment outcomes
| Patient group . | n . | % ORR (95% CI) . | Median PFS (95% CI), mo . | Median OS (95% CI), mo . |
|---|---|---|---|---|
| All patients | 206 | 47 (40-54) | 5.5 (4.6-5.7) | 16.3 (14.2-20.8) |
| No prior rituximab | 89 | 53 (42-63) | 5.6 (4.8-7.1)* | 20.2 (13.7-22.8) |
| Any prior rituximab | 117 | 43 (34-52) | 5.3 (4.0-5.7)* | 15.5 (10.4-18.6) |
| Rituximab monotherapy† (all prior) | 8 | 63 (24-91) | 4.9 (1.6-11.5) | 9.0 (4.3-NR) |
| Rituximab monotherapy‡ (as last prior) | 16 | 56 (30-80) | 4.6 (3.7-8.0) | NR (7.2-NR) |
| Rituximab combination§ (any prior) | 109 | 41 (32-51) | 5.3 (3.7-5.7) | 15.5 (10.7-18.6) |
| Rituximab combination§ (as last prior) | 101 | 41 (31-51) | 5.5 (3.7-5.7) | 15.5 (10.7-18.6) |
| Not refractory to last rituximab | 17 | 41 (18-67) | 4.6 (2.0-5.7) | 14.7 (7.7-27.6) |
| Refractory to last rituximab | 98 | 44 (34-54) | 5.5 (4.1-6.3) | 15.5 (10.4-18.6) |
| TTP > 3 months since last rituximab‖ | 51 | 47 (33-62) | 5.5 (3.7-6.1) | 23.0 (10.9-27.6) |
| TTP ≤ 3 months since last rituximab‖ | 56 | 39 (26-53) | 5.3 (3.7-6.3) | 14.8 (8.7-18.6) |
| > 10 months since last rituximab‖ | 64 | 50 (37-63) | 5.5 (3.7-6.0) | 17.3 (11.8-27.6)* |
| ≤ 10 months since last rituximab‖ | 53 | 34 (22-48) | 4.6 (3.7-5.9) | 10.4 (7.8-16.3)* |
| No prior FCR | 63 | 48 (35-61) | 5.5 (3.8-6.7)* | 17.1 (10.9-27.6) |
| Any prior FCR | 54 | 37 (24-51) | 4.6 (3.7-5.5)* | 14.2 (8.6-17.4) |
| Patient group . | n . | % ORR (95% CI) . | Median PFS (95% CI), mo . | Median OS (95% CI), mo . |
|---|---|---|---|---|
| All patients | 206 | 47 (40-54) | 5.5 (4.6-5.7) | 16.3 (14.2-20.8) |
| No prior rituximab | 89 | 53 (42-63) | 5.6 (4.8-7.1)* | 20.2 (13.7-22.8) |
| Any prior rituximab | 117 | 43 (34-52) | 5.3 (4.0-5.7)* | 15.5 (10.4-18.6) |
| Rituximab monotherapy† (all prior) | 8 | 63 (24-91) | 4.9 (1.6-11.5) | 9.0 (4.3-NR) |
| Rituximab monotherapy‡ (as last prior) | 16 | 56 (30-80) | 4.6 (3.7-8.0) | NR (7.2-NR) |
| Rituximab combination§ (any prior) | 109 | 41 (32-51) | 5.3 (3.7-5.7) | 15.5 (10.7-18.6) |
| Rituximab combination§ (as last prior) | 101 | 41 (31-51) | 5.5 (3.7-5.7) | 15.5 (10.7-18.6) |
| Not refractory to last rituximab | 17 | 41 (18-67) | 4.6 (2.0-5.7) | 14.7 (7.7-27.6) |
| Refractory to last rituximab | 98 | 44 (34-54) | 5.5 (4.1-6.3) | 15.5 (10.4-18.6) |
| TTP > 3 months since last rituximab‖ | 51 | 47 (33-62) | 5.5 (3.7-6.1) | 23.0 (10.9-27.6) |
| TTP ≤ 3 months since last rituximab‖ | 56 | 39 (26-53) | 5.3 (3.7-6.3) | 14.8 (8.7-18.6) |
| > 10 months since last rituximab‖ | 64 | 50 (37-63) | 5.5 (3.7-6.0) | 17.3 (11.8-27.6)* |
| ≤ 10 months since last rituximab‖ | 53 | 34 (22-48) | 4.6 (3.7-5.9) | 10.4 (7.8-16.3)* |
| No prior FCR | 63 | 48 (35-61) | 5.5 (3.8-6.7)* | 17.1 (10.9-27.6) |
| Any prior FCR | 54 | 37 (24-51) | 4.6 (3.7-5.5)* | 14.2 (8.6-17.4) |
NR indicates not reached.
P < .05. See text for details
Only type of prior rituximab therapy was monotherapy.
Can include patients who also received prior rituximab combination therapy.
Can include patients who also received rituximab monotherapy provided ≥ 1 rituximab combination therapy was received.
Median value used as cutoff.